Results 1 to 10 of about 6,075,026 (241)
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Hepatology, 2023 The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language.
M. Rinella +52 more
semanticscholar +1 more source
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Liver Cancer, 2023 Background: Primary liver cancer, of which around 75–85% is hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the ...
Jian Zhou +101 more
semanticscholar +1 more source
Deficiency of NOX1 or NOX4 Prevents Liver Inflammation and Fibrosis in Mice through Inhibition of Hepatic Stellate Cell Activation. [PDF]
, 2015 Reactive oxygen species (ROS) produced by nicotinamide adenine dinucleotide phosphate oxidase (NOX) play a key role in liver injury and fibrosis. Previous studies demonstrated that GKT137831, a dual NOX1/4 inhibitor, attenuated liver fibrosis in mice as ...
Brenner, David A +2 more
core +11 more sources
Journal of Experimental & Clinical Cancer Research, 2020 Background Hepatocellular carcinoma is the third top cause of cancer-related mortalities worldwide. The prognosis of HCC patients remains poor due to rapid progression and high incidence of tumor recurrence.
Hui Li +11 more
doaj +1 more source
Canadian Journal of Gastroenterology and Hepatology, 2022 Objectives. Factors prognostic of survival in liver transplant (LT) recipients with hepatitis B virus related acute-on-chronic liver failure (HBV-ACLF) remain unclear.
Zhengjun Zhou +6 more
doaj +1 more source
Cell Death and Disease, 2023 Multidrug resistance is a major challenge in treating advanced hepatocellular carcinoma (HCC). Although recent studies have reported that the multidrug resistance phenotype is associated with abnormal DNA methylation in cancer cells, the epigenetic ...
Xiao-Jun Guo +17 more
doaj +1 more source
MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease.
Gastroenterology, 2020 Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population, and has no approved drug therapy. While pharmacotherapies are in development, response rates appear modest.
M. Eslam, A. Sanyal, J. George
semanticscholar +1 more source
Assessing Non-Invasive Liver Function in Patients With Intestinal Failure Receiving Total Parenteral Nutrition-Results From the Prospective PNLiver Trial [PDF]
, 2020 Liver abnormalities in intestinal failure (IF) patients receiving parenteral nutrition (PN) can progress undetected by standard laboratory tests to intestinal failure associated liver disease (IFALD). The aim of this longitudinal study is to evaluate the
Bednarsch, Jan +10 more
core +1 more source
The role of RIPK1 mediated cell death in acute on chronic liver failure
Cell Death and Disease, 2021 Acute-on-chronic liver failure (ACLF) is characterized predominantly by non-apoptotic forms of hepatocyte cell death. Necroptosis is a form of programmed lytic cell death in which receptor interacting protein kinase (RIPK) 1, RIPK3 and phosphorylated ...
Takayuki Kondo +13 more
doaj +1 more source
Cancer Cell International, 2020 Background Plasmacytoid dendritic cells (pDCs) are present in various primary and metastatic human neoplasms; however, their clinical significance in intrahepatic cholangiocarcinoma is not clear.
Zhi-Qiang Hu +6 more
doaj +1 more source